Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?

Lakefront Biotherapeutics - Sponsored ADR (LKFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Oct 21, 2026

Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

Previously announced wind-down of the legacy cell therapy activities is substantially complete  Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that it has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer and formed by experienced executives Paul Stoffels, John Mellors and Peter Verhaeghe. The preclinical program is based on technology originated from, and research undertaken by AboundBio, which was acquired by Lakefront NV (previously Galapagos NV) in 2022.

GlobeNewsWire • Oct 14, 2026

Acquisition of Own Shares

Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between October 05, 2026 and October 09, 2026 it has repurchased 126,322 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 10/5/2026 XAMS 20,641 26.14 539,466.98 25.78 26.50 10/5/2026 TQEX 442 26.01 11,497.92 25.90 26.04 10/5/2026 CEUX 2,656 25.97 68,975.52 25.82 26.22 10/5/2026 AQEU 174 25.88 4,503.12 25.88 25.88 10/6/2026 XAMS 20,421 26.40 539,130.74 25.94 26.64 10/6/2026 TQEX 1,383 26.54 36,708.97 26.20 26.64 10/6/2026 CEUX 2,620 26.51 69,458.30 26.42 26.64 10/6/2026 AQEU 679 26.59 18,051.55 26.44 26.64 10/7/2026 XAMS 22,325 26.15 583,776.43 25.86 26.54 10/7/2026 CEUX 2,566 26.16 67,136.05 25.90 26.48 10/7/2026 AQEU 506 26.18 13,246.17 26.00 26.50 10/8/2026 XAMS 22,557 26.20 591,027.24 25.82 26.78 10/8/2026 TQEX 150 26.27 3,940.01 26.24 26.34 10/8/2026 CEUX 2,158 26.27 56,690.44 26.20 26.36 10/8/2026 AQEU 817 26.20 21,408.91 26.20 26.22 10/9/2026 XAMS 21,498 26.40 567,643.94 26.18 26.66 10/9/2026 TQEX 592 26.38 15,616.60 26.34 26.46 10/9/2026 CEUX 3,394 26.37 89,516.07 26.34 26.44 10/9/2026 AQEU 743 26.40 19,612.97 26.34 26.46 Total   126,322 26.26 3,317,407.94 25.78 26.78 As of market close on October 9, 2026, Lakefront holds 1,877,353 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

GlobeNewsWire • Oct 13, 2026

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

Lakefront Biotherapeutics American Depositary Shares NASDAQ: LKFT said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines.

MarketBeat • Sep 21, 2026

Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Lakefront Biotherapeutics: A Cash Discount With A More Credible Path To Value

Lakefront Biotherapeutics offers valuation support and clinical upside, leveraging a new development model post-Ouro acquisition and partnership with Gilead. LKFT's €2.24 billion liquidity and disciplined capital allocation provide runway through the first gamgertamig approval, with at least €1.6 billion projected post-approval. Gamgertamig's clinical promise targets difficult autoimmune diseases, but durable efficacy, safety, and competitive differentiation remain unproven and critical for future value.

Seeking Alpha • Sep 15, 2026

Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Mechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City at 5:35pm ET on Tuesday, September 15 th , 2026.

GlobeNewsWire • Sep 8, 2026

Lakefront Receives Transparency Notification from Bank of America

Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.

GlobeNewsWire • Aug 24, 2026

U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus

Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).

GlobeNewsWire • Aug 24, 2026

Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi

Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.

GlobeNewsWire • Jul 13, 2026